Exchange: NASDAQ·Updated 07:49 PM EDT

RAPP News

News
all
press releases
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Zacks
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
Zacks
More News
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Zacks
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.read more...
Benzinga
What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors?
Key PointsCOO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share...
Nasdaq News: Markets
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
Rapport Therapeutics, Inc. (RAPP) delivered earnings and revenue surprises of +24.66% and 0.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday
Rapport Therapeutics (NASDAQ:RAPP) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Receives Consensus Rating of "Buy" from Brokerages
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) has been assigned a consensus rating of "Buy" from the ten brokerages that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, seven have issued a buy rating and two have issued a s...
MarketBeat
Rapport Insider Sells $17.2 Million as Stock Surges 230% in a Year and Phase 3 Trials Near
Key PointsA major owner of Rapport Therapeutics reported selling 426,005 shares for a total value of approximately $17.18 million on April 17, 2026...
Nasdaq News: Markets
BTIG Research Reaffirms "Buy" Rating for Rapport Therapeutics (NASDAQ:RAPP)
BTIG Research restated a "buy" rating and issued a $53.00 target price on shares of Rapport Therapeutics in a research note on Wednesday...
MarketBeat
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) Insider Sells 20,225 Shares of Stock
Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) insider Krishnaswamy Yeleswaram sold 20,225 shares of Rapport Therapeutics stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $39.99, for a total value of $808,797.75. Following the transaction, the...
MarketBeat

Advertisement|Remove ads.